Tags

Type your tag names separated by a space and hit enter

Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
Cancer Invest. 2020 Jul; 38(6):365-371.CI

Abstract

Immunotherapy is standard first-line therapy for advanced non-small cell lung cancer (NSCLC) either alone or in combination with chemotherapy. Despite significant benefits, immune checkpoint inhibitors (ICI) can cause toxicities within any organ, termed immune related adverse events. Pneumonitis is a potentially life-threatening complication of ICIs. Currently, there are no established guidelines for use of ICIs in patients with underlying autoimmune or interstitial lung disease (ILD) and few studies have been published. We present a case of first-line ICI-chemotherapy in a patient with metastatic NSCLC and ILD who suffered treatment related lung toxicity and acute worsening ILD, which lead to his death.

Authors+Show Affiliations

Division of Hematology and Oncology, Department of Internal Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USA.Division of Hematology and Oncology, Department of Internal Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USA.

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

32559143

Citation

L Gemmill, Julie Anne, and Amna Sher. "Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient With Non-Small Cell Lung Cancer: a Case Presentation and Review of the Literature." Cancer Investigation, vol. 38, no. 6, 2020, pp. 365-371.
L Gemmill JA, Sher A. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. Cancer Invest. 2020;38(6):365-371.
L Gemmill, J. A., & Sher, A. (2020). Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. Cancer Investigation, 38(6), 365-371. https://doi.org/10.1080/07357907.2020.1783677
L Gemmill JA, Sher A. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient With Non-Small Cell Lung Cancer: a Case Presentation and Review of the Literature. Cancer Invest. 2020;38(6):365-371. PubMed PMID: 32559143.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. AU - L Gemmill,Julie Anne, AU - Sher,Amna, Y1 - 2020/07/02/ PY - 2020/6/20/pubmed PY - 2020/7/29/medline PY - 2020/6/20/entrez KW - Immune checkpoint inhibitors (ICI) KW - immunotherapy KW - interstitial lung disease (ILD) KW - non-small cell lung cancer (NSCLC) KW - pneumonitis SP - 365 EP - 371 JF - Cancer investigation JO - Cancer Invest. VL - 38 IS - 6 N2 - Immunotherapy is standard first-line therapy for advanced non-small cell lung cancer (NSCLC) either alone or in combination with chemotherapy. Despite significant benefits, immune checkpoint inhibitors (ICI) can cause toxicities within any organ, termed immune related adverse events. Pneumonitis is a potentially life-threatening complication of ICIs. Currently, there are no established guidelines for use of ICIs in patients with underlying autoimmune or interstitial lung disease (ILD) and few studies have been published. We present a case of first-line ICI-chemotherapy in a patient with metastatic NSCLC and ILD who suffered treatment related lung toxicity and acute worsening ILD, which lead to his death. SN - 1532-4192 UR - https://www.unboundmedicine.com/medline/citation/32559143/Anti-PD-1-Related_Exacerbation_of_Interstitial_Lung_Disease_in_a_Patient_with_Non-Small_Cell_Lung_Cancer:_A_Case_Presentation_and_Review_of_the_Literature L2 - http://www.tandfonline.com/doi/full/10.1080/07357907.2020.1783677 DB - PRIME DP - Unbound Medicine ER -